Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting
02 mai 2022 16h35 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two poster...
Codexis to Report First Quarter 2022 Financial Results on May 5
21 avr. 2022 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will...
Codexis and seqWell Announce Strategic Investment and Partnership Initiation
21 avr. 2022 08h00 HE
|
Codexis, Inc.
seqWell raises $7M Series C funding, led by CodexisCurrent investors Research Corporation Technologies and BroadOak Capital Partners also participated in the roundNew funding will be used to...
Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis
12 avr. 2022 08h00 HE
|
Codexis, Inc.
Molecular Assemblies has pioneered Fully Enzymatic Synthesis™ (or FES™) technology with an in-process purification step to overcome the length, purity, and accuracy limitations of the current chemical...
Codexis to Participate in the Cowen 42nd Annual Health Care Conference
01 mars 2022 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management...
Codexis Reports Fourth Quarter and Fiscal Year 2021 Financial Results
24 févr. 2022 16h05 HE
|
Codexis, Inc.
Record Annual Total Revenue of $104.8M, Representing Eighth Consecutive Year of Revenue Growth Company Guides to 2022 Total Revenues of $152-$158M; Product Revenues of $112-$118M REDWOOD CITY,...
Codexis to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
10 févr. 2022 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will...
Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria
24 janv. 2022 08h00 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the U.S....
Codexis to Participate in the H.C. Wainwright Virtual BioConnect Conference
05 janv. 2022 08h00 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management...
Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing
15 déc. 2021 08h00 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of...